{"id":27786,"date":"2024-08-07T09:27:39","date_gmt":"2024-08-07T07:27:39","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=27786"},"modified":"2024-08-07T09:27:39","modified_gmt":"2024-08-07T07:27:39","slug":"cinven-blir-huvudinvesterare-i-vitamin-well","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/uppdrag\/cinven-blir-huvudinvesterare-i-vitamin-well\/","title":{"rendered":"Cinven blir huvudinvesterare i Vitamin Well"},"content":{"rendered":"<p class=\"preamble\">Det internationella private equity-bolaget Cinven, som fokuserar p\u00e5 att bygga globala och europeiska f\u00f6retag i v\u00e4rldsklass, har ing\u00e5tt avtal om att bli huvudinvesterare i Vitamin Well, en svensk leverant\u00f6r av proteinbars samt sport- och h\u00e4lsodrycker.<\/p>\n<p>Den nuvarande majoritetsinvesteraren, Bridgepoint, kommer att bibeh\u00e5lla en betydande minoritetsandel i Vitamin Well. Transaktionen \u00e4r f\u00f6rem\u00e5l f\u00f6r myndighetsgodk\u00e4nnande och andra sedvanliga villkor f\u00f6r slutf\u00f6rande.<\/p>\n<p>Vitamin Well, med huvudkontor i Stockholm, grundades 2008 och \u00e4r ett snabbv\u00e4xande f\u00f6retag inom funktionell mat och dryck som erbjuder premiumprodukter f\u00f6r h\u00e4lsomedvetna och aktiva konsumenter. Vitamin Well har cirka 500 anst\u00e4llda och en bred produktportf\u00f6lj med flera varum\u00e4rken, d\u00e4ribland Vitamin Well, NOCCO och Barebells, som s\u00e4ljs internationellt p\u00e5 mer \u00e4n 40 marknader.<\/p>\n<p>Cinven r\u00e5dgavs i transaktionen av Mannheimer Swartling, som samarbetade med den globala advokatbyr\u00e5n Freshfields Bruckhaus Deringer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Det internationella private equity-bolaget Cinven, som fokuserar p\u00e5 att bygga globala och europeiska f\u00f6retag i v\u00e4rldsklass, har ing\u00e5tt avtal om att bli huvudinvesterare i Vitamin\u2026<\/p>\n","protected":false},"author":16,"featured_media":27787,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3469],"tags":[],"class_list":["post-27786","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uppdrag","business-group-foretagsoverlatelser","business-group-healthcare-and-life-sciences","business-group-private-equity"],"acf":[],"lang":"sv","translations":{"sv":27786,"en":27791},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/27786"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=27786"}],"version-history":[{"count":2,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/27786\/revisions"}],"predecessor-version":[{"id":27790,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/27786\/revisions\/27790"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/27787"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=27786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=27786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=27786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}